Regulatory authorities using identical trial data made substantially different decisions regarding both safety and efficacy of hypoglycemic drugs. The differences in initial indication wording between Japan and the other authorities suggest that trial data and T2D are interpreted differently in these regions (British Journal of Clinical Pharmacology)
Please join us for a series of vibrant and thought-provoking presentations by leaders in these fields who will discuss the results of recent pivotal trials in these areas. Live online discussions focusing on implementation of novel efficacious therapies will challenge clinicians as to how to adapt their daily practice.
Guidelines for early-onset adult type 2 diabetes are extrapolated predominantly from evidence in older individuals. Strategies to support the participation of individuals with early-onset adult type 2 diabetes in future research are imperative to ensure guidelines for these high-risk individuals are evidence-based (Diabetologia)
Poor medication adherence is primarily why RW effectiveness is significantly less than RCT efficacy, suggesting an urgent need to effectively address adherence among patients with type 2 diabetes (Diabetes Care)
A review of the results of completed CVOTs of glucose-lowering medications and suggest a possible treatment algorithm based on cardiac and renal co-morbidities to translate cardiovascular outcome trials findings into clinical practice (Cardiovascular Diabetology)